{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T15:45:57Z","timestamp":1789919157232,"version":"4.0.1"},"reference-count":104,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":311,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Oxford Biomedical Research Centre"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Axial spondyloarthritis (axSpA) is a chronic illness with limited treatment options. The role of Janus kinase (JAK) inhibition as a therapeutic option has increasingly become a focus of research in recent years as they have brought a new mode of action to the clinical armamentarium. This review assesses the efficacy and safety profile of these drugs in axSpA. The current phase 2 and 3 clinical trials data are summarized across tofacitinib, upadacitinib and filgotinib. Moreover, the safety profiles of these drugs, in the context of emerging safety signals such as during the ORAL surveillance study, are reviewed. In summary, JAK inhibitors offer a novel therapeutic target for axSpA and appear to address some of the unmet needs for patients who have either failed to respond to current treatment options or in whom they are contraindicated. There is a relative lack of evidence in non-radiographic axSpA and longer-term trials are needed to establish true efficacy and safety profile in radiographic axSpA.<\/jats:p>","DOI":"10.1093\/rap\/rkae141","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T17:56:30Z","timestamp":1731002190000},"source":"Crossref","is-referenced-by-count":9,"title":["Rationale and concerns for using JAK inhibitors in axial spondyloarthritis"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9829-2758","authenticated-orcid":false,"given":"Saad","family":"Ahmed","sequence":"first","affiliation":[{"name":"General Medicine, Colchester Hospital , Colchester,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8424-144X","authenticated-orcid":false,"given":"Rohan","family":"Yesudian","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, University of Cambridge , Cambridge,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6341-9616","authenticated-orcid":false,"given":"Hassan","family":"Ubaide","sequence":"additional","affiliation":[{"name":"General Medicine, Colchester Hospital , Colchester,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4756-663X","authenticated-orcid":false,"given":"Laura C","family":"Coates","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford , Oxford,","place":["UK"]},{"name":"Oxford NIHR Biomedical Research Centre, Oxford University Hospitals NHS Trust , Oxford,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"key":"2024121022513618900_rkae141-B1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/1759720X18773726","article-title":"Ankylosing spondylitis and axial spondyloarthritis: recent insights and impact of new classification criteria","volume":"10","author":"Proft","year":"2018","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2024121022513618900_rkae141-B2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/rheumatology\/key070","article-title":"The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis","volume":"58","author":"Veale","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2024121022513618900_rkae141-B3","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2024121022513618900_rkae141-B4","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024121022513618900_rkae141-B5","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/art.23275","article-title":"Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs","volume":"58","author":"Song","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2024121022513618900_rkae141-B6","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1136\/ard.2006.052878","article-title":"Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial","volume":"65","author":"Braun","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2024121022513618900_rkae141-B7","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/ard.2006.054098","article-title":"No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial","volume":"66","author":"Haibel","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2024121022513618900_rkae141-B8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024121022513618900_rkae141-B9","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2024121022513618900_rkae141-B10","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1002\/art.23606","article-title":"Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two","volume":"58","author":"Haibel","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2024121022513618900_rkae141-B11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study","volume":"73","author":"Landew\u00e9","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2024121022513618900_rkae141-B12","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1136\/ard.2006.056747","article-title":"Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis","volume":"65","author":"van der Heijde","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2024121022513618900_rkae141-B13","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1136\/annrheumdis-2015-207596","article-title":"Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study","volume":"75","author":"Maksymowych","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2024121022513618900_rkae141-B14","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"2024121022513618900_rkae141-B15","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2024121022513618900_rkae141-B16","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1002\/art.39257","article-title":"A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis","volume":"67","author":"Sieper","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2024121022513618900_rkae141-B17","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"2024121022513618900_rkae141-B18","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","article-title":"Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3","volume":"19","author":"Pavelka","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2024121022513618900_rkae141-B19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40744-018-0123-5","article-title":"Efficacy and safety of secukinumab 150 mg with and without loading regimen in ankylosing spondylitis: 104-week results from MEASURE 4 study","volume":"5","author":"Kivitz","year":"2018","journal-title":"Rheumatol Ther"},{"key":"2024121022513618900_rkae141-B20","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/art.41477","article-title":"Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled phase III study","volume":"73","author":"Deodhar","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2024121022513618900_rkae141-B21","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1002\/art.42852","article-title":"Effect of secukinumab versus adalimumab biosimilar on radiographic progression in patients with radiographic axial spondyloarthritis: results from a head-to-head randomized phase IIIb study","volume":"76","author":"Baraliakos","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2024121022513618900_rkae141-B22","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","article-title":"Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"2024121022513618900_rkae141-B23","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/annrheumdis-2019-216118","article-title":"Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)","volume":"79","author":"Dougados","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024121022513618900_rkae141-B24","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/art.40753","article-title":"Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2024121022513618900_rkae141-B25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","article-title":"Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"2024121022513618900_rkae141-B26","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1136\/ard-2022-223595","article-title":"Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials","volume":"82","author":"van der Heijde","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024121022513618900_rkae141-B27","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1136\/annrheumdis-2020-216980","article-title":"Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study","volume":"79","author":"van der Heijde","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024121022513618900_rkae141-B28","first-page":"27","article-title":"Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults","volume":"38","author":"Erdes","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"2024121022513618900_rkae141-B29","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1136\/annrheumdis-2020-219406","article-title":"Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial","volume":"80","author":"Wei","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2024121022513618900_rkae141-B30","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2024121022513618900_rkae141-B31","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/art.30223","article-title":"Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial","volume":"63","author":"Braun","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2024121022513618900_rkae141-B32","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/1759720X17706454","article-title":"Tumor necrosis factor-\u03b1 (TNF\u03b1) inhibitors in the treatment of nonradiographic axial spondyloarthritis: current evidence and place in therapy","volume":"9","author":"Rios Rodriguez","year":"2017","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2024121022513618900_rkae141-B33","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/annrheumdis-2017-212377","article-title":"Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial","volume":"77","author":"van der Heijde","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2024121022513618900_rkae141-B34","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","article-title":"Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)","volume":"72","author":"Sieper","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2024121022513618900_rkae141-B35","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/ard.2010.139667","article-title":"Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial","volume":"70","author":"Song","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2024121022513618900_rkae141-B36","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1093\/rheumatology\/keac522","article-title":"Brodalumab, an anti-interleukin-17 receptor A monoclonal antibody, in axial spondyloarthritis: 68-week results from a phase 3 study","volume":"62","author":"Kim","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2024121022513618900_rkae141-B37","doi-asserted-by":"crossref","first-page":"376","DOI":"10.47360\/1995-4484-2020-376-386","article-title":"Efficacy and safety of netakimab, anti-IL-17A monoclonal antibody, in patients with ankylosing spondylitis. Results of phase III international, multicenter, randomized double-blind clinical trial BCD-085-5\/ASTERA","volume":"58","author":"Mazurov","year":"2020","journal-title":"Rheumatol Sci Pract"},{"key":"2024121022513618900_rkae141-B38","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","article-title":"Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165","volume":"62","author":"Wrobleski","year":"2019","journal-title":"J Med Chem"},{"key":"2024121022513618900_rkae141-B39","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2024121022513618900_rkae141-B40","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1093\/rheumatology\/ker194","article-title":"Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years\u2014early clinical response predicts long-term outcome","volume":"50","author":"Baraliakos","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"2024121022513618900_rkae141-B41","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s40744-020-00269-6","article-title":"Achievement of remission endpoints with secukinumab over 3 years in active ankylosing spondylitis: pooled analysis of two phase 3 studies","volume":"8","author":"Baraliakos","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2024121022513618900_rkae141-B42","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1007\/s10067-020-05319-6","article-title":"Influence of smoking and obesity on treatment response in patients with axial spondyloarthritis: a systematic literature review","volume":"40","author":"Zurita Prada","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2024121022513618900_rkae141-B43","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3389\/fimmu.2020.00312","article-title":"Immunogenicity of TNF-inhibitors","volume":"11","author":"Atiqi","year":"2020","journal-title":"Front Immunol"},{"key":"2024121022513618900_rkae141-B44","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3899\/jrheum.17666","article-title":"The sex influence on response to tumor necrosis factor-\u03b1 inhibitors and remission in axial spondyloarthritis","volume":"45","author":"Lubrano","year":"2018","journal-title":"J Rheumatol"},{"key":"2024121022513618900_rkae141-B45","doi-asserted-by":"crossref","first-page":"e000524","DOI":"10.1136\/rmdopen-2017-000524","article-title":"Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature review","volume":"3","author":"Navarro-Comp\u00e1n","year":"2017","journal-title":"RMD Open"},{"key":"2024121022513618900_rkae141-B46","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13075-016-0969-2","article-title":"Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort","volume":"18","author":"Ciurea","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2024121022513618900_rkae141-B47","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/ard-2022-223298","article-title":"Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis","volume":"82","author":"Webers","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024121022513618900_rkae141-B48","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/annrheumdis-2016-210023","article-title":"Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study","volume":"76","author":"Sieper","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024121022513618900_rkae141-B49","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/annrheumdis-2013-203559","article-title":"Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2024121022513618900_rkae141-B50","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1136\/ard.2004.023176","article-title":"Open label trial of anakinra in active ankylosing spondylitis over 24 weeks","volume":"64","author":"Haibel","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2024121022513618900_rkae141-B51","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/art.27383","article-title":"Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial","volume":"62","author":"Song","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2024121022513618900_rkae141-B52","doi-asserted-by":"crossref","first-page":"iv28","DOI":"10.1093\/rheumatology\/keab617","article-title":"IL-23 and axial disease: do they come together?","volume":"60","author":"Mease","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2024121022513618900_rkae141-B53","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/nm.2854","article-title":"Primed for inflammation: enthesis-resident T cells","volume":"18","author":"Lories","year":"2012","journal-title":"Nat Med"},{"key":"2024121022513618900_rkae141-B54","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3389\/fimmu.2018.01550","article-title":"The initiation, but not the persistence, of experimental spondyloarthritis is dependent on interleukin-23 signaling","volume":"9","author":"van Tok","year":"2018","journal-title":"Front Immunol"},{"key":"2024121022513618900_rkae141-B55","doi-asserted-by":"crossref","first-page":"e0168958","DOI":"10.1371\/journal.pone.0168958","article-title":"Impact of dose tapering of tumor necrosis factor inhibitor on radiographic progression in ankylosing spondylitis","volume":"11","author":"Park","year":"2016","journal-title":"PLoS One"},{"key":"2024121022513618900_rkae141-B56","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13075-018-1556-5","article-title":"Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial","volume":"20","author":"van der Heijde","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2024121022513618900_rkae141-B57","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s40744-020-00214-7","article-title":"Induction of sustained clinical remission in early axial spondyloarthritis following certolizumab pegol treatment: 48-week outcomes from C-OPTIMISE","volume":"7","author":"Landew\u00e9","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2024121022513618900_rkae141-B58","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"2024121022513618900_rkae141-B59","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41584-023-01034-z","article-title":"Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis","volume":"19","author":"Bautista-Molano","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2024121022513618900_rkae141-B60","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement","volume":"80","author":"Nash","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2024121022513618900_rkae141-B61","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13075-019-1964-1","article-title":"Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations","volume":"21","author":"McInnes","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2024121022513618900_rkae141-B62","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1136\/annrheumdis-2021-eular.1894","article-title":"Pos0920 Targeted serum proteomic analysis following upadacitinib treatment in ankylosing spondylitis shows robust suppression of innate and adaptive immune pathways with tissue repair modulation","volume":"80","author":"Sornasse","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2024121022513618900_rkae141-B63","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1136\/annrheumdis-2016-209454","article-title":"A20 inhibition of STAT1 expression in myeloid cells: a novel endogenous regulatory mechanism preventing development of enthesitis","volume":"76","author":"De Wilde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024121022513618900_rkae141-B64","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/art.38218","article-title":"Combination of tumor necrosis factor \u03b1 and interleukin-6 induces mouse osteoclast-like cells with bone resorption activity both in vitro and in vivo","volume":"66","author":"Yokota","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2024121022513618900_rkae141-B65","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"2024121022513618900_rkae141-B66","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3109\/08977194.2012.660936","article-title":"Biology and significance of the JAK\/STAT signalling pathways","volume":"30","author":"Kiu","year":"2012","journal-title":"Growth Factors"},{"key":"2024121022513618900_rkae141-B67","doi-asserted-by":"crossref","first-page":"i17","DOI":"10.1093\/rheumatology\/key225","article-title":"Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Taylor","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2024121022513618900_rkae141-B68","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/art.38291","article-title":"The IL-23\/IL-17 axis in spondyloarthritis pathogenesis: Th17 and beyond","volume":"66","author":"Smith","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2024121022513618900_rkae141-B69","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.0105-2896.2004.00214.x","article-title":"IL-12 and IL-23: master regulators of innate and adaptive immunity","volume":"202","author":"Langrish","year":"2004","journal-title":"Immunol Rev"},{"key":"2024121022513618900_rkae141-B70","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1136\/annrheumdis-2016-211046","article-title":"Regulatory role of the JAK STAT kinase signalling system on the IL-23\/IL-17 cytokine axis in psoriatic arthritis","volume":"76","author":"Raychaudhuri","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024121022513618900_rkae141-B71","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024121022513618900_rkae141-B72","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","article-title":"Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study","volume":"80","author":"Deodhar","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2024121022513618900_rkae141-B73","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"2024121022513618900_rkae141-B74","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1093\/rheumatology\/keab758","article-title":"Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial","volume":"61","author":"Maksymowych","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2024121022513618900_rkae141-B75","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet"},{"key":"2024121022513618900_rkae141-B76","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/ard-2022-222608","article-title":"Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial","volume":"81","author":"van der Heijde","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2024121022513618900_rkae141-B77","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","article-title":"Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Deodhar","year":"2022","journal-title":"Lancet"},{"key":"2024121022513618900_rkae141-B78","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/art.41206","article-title":"Effect of therapy on radiographic progression in axial spondyloarthritis: a systematic review and meta-analysis","volume":"72","author":"Karmacharya","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 1","key":"2024121022513618900_rkae141-B79","first-page":"882","article-title":"Pos1115 Effect of secukinumab versus adalimumab biosimilar on radiographic progression in patients with radiographic axial spondyloarthritis: subgroup analyses by baseline syndesmophytes and C-reactive protein status","volume":"82","author":"Baraliakos","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024121022513618900_rkae141-B80","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/art.21197","article-title":"Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept","volume":"52","author":"Braun","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2024121022513618900_rkae141-B81","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/ard.2008.103192","article-title":"Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials","volume":"69","author":"Sieper","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2024121022513618900_rkae141-B82","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.3899\/jrheum.131289","article-title":"Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis","volume":"41","author":"van Denderen","year":"2014","journal-title":"J Rheumatol"},{"key":"2024121022513618900_rkae141-B83","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/annrheumdis-2016-210931","article-title":"Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register","volume":"76","author":"Lie","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024121022513618900_rkae141-B84","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn\u2019s disease: results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"key":"2024121022513618900_rkae141-B85","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn\u2019s disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"2024121022513618900_rkae141-B86","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"2024121022513618900_rkae141-B87","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"key":"2024121022513618900_rkae141-B88","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024121022513618900_rkae141-B89","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40273-023-01244-z","article-title":"Filgotinib for treating moderately to severely active ulcerative colitis: an evidence review group perspective of a NICE single technology appraisal","volume":"41","author":"van Asselt","year":"2023","journal-title":"Pharmacoeconomics"},{"key":"2024121022513618900_rkae141-B90","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn\u2019s disease","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"2024121022513618900_rkae141-B91","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Mease","year":"2018","journal-title":"Lancet"},{"key":"2024121022513618900_rkae141-B92","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2024121022513618900_rkae141-B93","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2024121022513618900_rkae141-B94","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/annrheumdis-2011-201108","article-title":"Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"72","author":"Galloway","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2024121022513618900_rkae141-B95","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"2024121022513618900_rkae141-B96","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"Lancet"},{"key":"2024121022513618900_rkae141-B97","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet"},{"key":"2024121022513618900_rkae141-B98","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA"},{"key":"2024121022513618900_rkae141-B99","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/art.41580","article-title":"Venous thromboembolism risk with JAK inhibitors: a meta-analysis","volume":"73","author":"Yates","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2024121022513618900_rkae141-B100","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","article-title":"Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study","volume":"81","author":"Khosrow-Khavar","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2024121022513618900_rkae141-B101","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/ard-2022-222824","article-title":"Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study","volume":"82","author":"Hoisnard","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024121022513618900_rkae141-B102","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1002\/art.42862","article-title":"Risk of gastrointestinal perforation in patients with rheumatic diseases exposed to Janus kinase inhibitors versus adalimumab: a nationwide cohort study","volume":"76","author":"Hoisnard","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2024121022513618900_rkae141-B103","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/art.41911","article-title":"Safety and efficacy of upadacitinib in patients with active ankylosing spondylitis and an inadequate response to nonsteroidal antiinflammatory drug therapy: one-year results of a double-blind, placebo-controlled study and open-label extension","volume":"74","author":"Deodhar","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2024121022513618900_rkae141-B104","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.3899\/jrheum.160363","article-title":"Predictors of loss of remission and disease flares in patients with axial spondyloarthritis receiving antitumor necrosis factor treatment: a retrospective study","volume":"43","author":"Lubrano","year":"2016","journal-title":"J Rheumatol"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumap\/advance-article-pdf\/doi\/10.1093\/rap\/rkae141\/60482123\/rkae141.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/8\/4\/rkae141\/60972809\/rkae141.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/8\/4\/rkae141\/60972809\/rkae141.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T22:53:51Z","timestamp":1733871231000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkae141\/7885166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":104,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,9,14]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkae141","relation":{},"ISSN":["2514-1775"],"issn-type":[{"value":"2514-1775","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024]]},"published":{"date-parts":[[2024]]},"article-number":"rkae141"}}